Allisartan Isoproxil/Indapamide

阿利沙坦酯/吲达帕胺

Report date: 2025/06/12 10:31:19
NME

Base Information

Drug NameAllisartan Isoproxil/Indapamide
Drug Alias Name阿利沙坦酯吲达帕胺阿利沙坦酯吲达帕胺缓释片（深圳信立泰）复立安SAL0108SAL-0108
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsSymporters inhibitors
TargetsAngiotensin II Receptor Type 1Symporters
Therapy Area/IndicationsEssential Hypertension
Global Approved IndicationsEssential Hypertension
Approved Indications in ChinaEssential Hypertension
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryMainland China
CombinationsYes Allisartan IsoproxilIndapamide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
Inactive CompaniesBeijing Joekai Biotechnology Llc
Active IndicationsEssential Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A